Want to see CCEL full AI Analyst Report?
Top Page
Cryo-Cell International
(CCEL)
Select Model
Select Model
Rating:45Neutral
Price Target:
$3.50
▼(-17.26% Downside)
Action:Reiterated
Date:10/10/26
The score is held down primarily by weak financial performance—net losses, flat-to-down revenue, and especially the deeply negative equity position—despite positive recent free cash flow. Technicals provide modest support with price trading above key moving averages, but momentum indicators are mixed. Valuation remains a concern due to negative earnings and no dividend yield data.
Positive Factors
Recurring revenue model
The combination of upfront processing fees and recurring long-term storage charges can create revenue durability beyond each individual enrollment. As the stored client base grows and retention remains steady, the model may support a recurring revenue foundation and more predictable cash generation.
Negative Factors
Deeply negative equity
Deeply negative equity signals accumulated balance-sheet deficits and materially reduces financial flexibility. It can constrain the company’s ability to absorb operating setbacks, support growth investments, or access financing on favorable terms until sustained earnings and cash generation rebuild the capital base.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue model
The combination of upfront processing fees and recurring long-term storage charges can create revenue durability beyond each individual enrollment. As the stored client base grows and retention remains steady, the model may support a recurring revenue foundation and more predictable cash generation.
Read all positive factors
Cryo-Cell International (CCEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.92M
Dividend Yield13.4%
Average Volume (3M)13.82K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth-1.96%
EPS Growth-314.41%
CountryUS
Employees74
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.22
Shares Outstanding8,062,650
10 Day Avg. Volume13,064
30 Day Avg. Volume13,820
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.73
Price to Sales (P/S)1.02
P/FCF Ratio6.12
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue1.24
Enterprise Value/Gross Profit1.59
Enterprise Value/Ebitda32.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)$30.04M
Cryo-Cell International Business Overview & Revenue Model
Company Description
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical...
How the Company Makes Money
CCEL primarily generates revenue from fees associated with private (family) cord blood and cord tissue banking services. The company’s revenue model typically includes: (1) upfront service fees charged at or around the time of birth for collection...
Cryo-Cell International Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
22
Negative
Cash Flow
62
Positive
| Breakdown | TTM | Nov 2025 | Feb 2025 | Nov 2023 | Feb 2023 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.13M | 31.57M | 31.99M | 31.34M | 30.34M | 28.88M |
| Gross Profit | 24.26M | 24.19M | 24.04M | 22.90M | 21.54M | 19.90M |
| EBITDA | 1.20M | 1.10M | 1.96M | -10.42M | 6.65M | 5.32M |
| Net Income | -2.82M | -2.43M | 402.10K | -9.52M | 2.77M | 2.08M |
Balance Sheet | ||||||
| Total Assets | 62.30M | 61.73M | 64.68M | 61.22M | 64.89M | 60.66M |
| Cash, Cash Equivalents and Short-Term Investments | 4.23M | 3.30M | 3.50M | 980.25K | 1.72M | 8.34M |
| Total Debt | 577.20K | 11.56M | 12.93M | 10.90M | 11.61M | 2.82M |
| Total Liabilities | 78.70M | 80.33M | 77.89M | 72.25M | 66.41M | 56.48M |
| Stockholders Equity | -16.39M | -18.61M | -13.22M | -11.03M | -1.52M | 4.18M |
Cash Flow | ||||||
| Free Cash Flow | 4.65M | 5.25M | 2.41M | 1.28M | -8.60M | 974.92K |
| Operating Cash Flow | 4.92M | 5.48M | 6.01M | 8.92M | 8.57M | 7.93M |
| Investing Cash Flow | -416.26K | -975.33K | -4.88M | -8.14M | -15.28M | -6.95M |
| Financing Cash Flow | -3.34M | -4.75M | -979.12K | -2.07M | 147.86K | -3.07M |
Cryo-Cell International Technical Analysis
Positive
4.23
Price Trends
4.19
Positive
3.86
Positive
3.64
Positive
Market Momentum
0.12
Negative
53.84
Neutral
72.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Positive. The current price of 4.23 is above the 20-day moving average (MA) of 4.23, above the 50-day MA of 4.19, and above the 200-day MA of 3.64, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 53.84 is Neutral, neither overbought nor oversold. The STOCH value of 72.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCEL.
Cryo-Cell International Risk Analysis
Cryo-Cell International disclosed 40 risk factors in its most recent earnings report. Cryo-Cell International reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cryo-Cell International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $412.26M | 9.33 | 14.27% | ― | 0.64% | 19.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $35.92M | -19.87 | 15.84% | 13.40% | -1.96% | -314.41% | |
40 Underperform | $17.63M | -0.03 | 5.16% | 2.02% | 20.26% | 69.68% | |
39 Underperform | $3.00M | -0.31 | -387.27% | ― | ― | ― |
* Healthcare Sector Average
CCEL
Cryo-Cell International
4.46
-0.12
-2.52%
CCM
Concord Medical Services
4.06
-1.46
-26.45%
SRTA
Strata Critical Medical
4.66
-0.35
-6.99%
NIVF
NewGenIvf Group
1.46
-20,596.31
-99.99%
BMGL
Basel Medical Group Ltd
4.44
-14.28
-76.28%
AIDX
20/20 Biolabs, Inc.
0.24
-23.62
-99.01%
Cryo-Cell International Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Cryo-Cell Sets Record Date for 2026 Shareholder Meeting
Neutral
Sep 14, 2026
Cryo-Cell International’s board of directors has scheduled the company’s 2026 Annual Meeting of Stockholders for October 27, 2026, and set September 21, 2026 as the record date to determine shareholders eligible to receive notice and v...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.